Posted by Michael Wonder on 06 Sep 2022
Bristol Myers Squibb’s acute myeloid leukaemia oral maintenance therapy recommended by NICE
6 September 2022 - Phase 3 trial results show Onureg offers significantly longer overall and relapse-free survival.
Bristol Myers Squibb has announced that NICE has issued a Final Appraisal Document recommending Onureg – oral azacitidine – for maintenance therapy in adult patients with acute myeloid leukaemia.
